MannKind Corporation (MNKD) Shares are Down -2.13%

MannKind Corporation (MNKD) : During the past 4 weeks, traders have been relatively bearish on MannKind Corporation (MNKD), hence the stock is down -2.57% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.1% relative to the S&P 500. The 4-week change in the price of the stock is -2.19% and the stock has fallen -2.13% in the past 1 week.

MannKind Corp. is up 6.76% in the last 3-month period. Year-to-Date the stock performance stands at -32.68%. The stock has recorded a 20-day Moving Average of 1.01% and the 50-Day Moving Average is 6.84%.


MannKind Corporation (NASDAQ:MNKD): The stock opened at $0.98 on Friday but the bulls could not build on the opening and the stock topped out at $0.99 for the day. The stock traded down to $0.96 during the day, due to lack of any buying support eventually closed down at $0.98 with a loss of -1.20% for the day. The stock had closed at $0.99 on the previous day. The total traded volume was 1,730,169 shares.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.